Browse by UCL Departments and Centres
![[up]](/style/images/multi_up.png)
Up a levelGroup by: Author | Type
Number of items: 40.
B
Bangham, M;
Goldstein, R;
Walton, H;
Ledermann, JA;
(2016)
Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease.
Gynecologic Oncology Reports
, 18
pp. 22-24.
10.1016/j.gore.2016.10.004.
|
 |
|
Beeken, RJ;
Croker, H;
Heinrich, M;
Smith, L;
Williams, K;
Hackshaw, A;
Hines, J;
... Fisher, A; + view all
(2016)
Study protocol for a randomised controlled trial of brief, habit-based, lifestyle advice for cancer survivors: exploring behavioural outcomes for the Advancing Survivorship Cancer Outcomes Trial (ASCOT).
BMJ Open
, 6
(11)
, Article e011646. 10.1136/bmjopen-2016-011646.
|
|
|
Bridgewater, J;
Lopes, A;
Beare, S;
Duggan, M;
Lee, D;
Ricamara, M;
McEntee, D;
... Valle, JW; + view all
(2016)
A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.
BMC Cancer
, 16
(1)
p. 153.
10.1186/s12885-016-2174-8.
|
|
|
Brown, N;
McBain, C;
Nash, S;
Hopkins, K;
Sanghera, P;
Saran, F;
Phillips, M;
... Mulholland, P; + view all
(2016)
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
PLoS ONE
, 11
(5)
10.1371/journal.pone.0156369.
|
C
|
Childs, A;
Kirkwood, A;
Edeline, J;
Tu, VL;
Watkins, J;
Lamarca, A;
Alrifai, D;
... Meyer, T; + view all
(2016)
Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours.
Endocrine-Related Cancer
, 23
(7)
pp. 563-570.
10.1530/ERC-16-0099.
|
|
D
|
de Boer, SM;
Powell, ME;
Mileshkin, L;
Katsaros, D;
Bessette, P;
Haie-Meder, C;
Ottevanger, PB;
... Creutzberg, CL; + view all
(2016)
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
Lancet Oncology
, 17
(8)
pp. 1114-1126.
10.1016/S1470-2045(16)30120-6.
|
|
|
De Ruysscher, D;
Lueza, B;
Le Péchoux, C;
Johnson, DH;
O'Brien, M;
Murray, N;
Spiro, S;
... RTT-SCLC Collaborative Group; + view all
(2016)
Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.
Annals of Oncology
, 27
(10)
pp. 1818-1828.
10.1093/annonc/mdw263.
|
|
E
|
Eminowicz, GKD;
(2016)
Standardisation and optimisation of radical radiotherapy for cervical cancer.
Doctoral thesis , UCL (University College London).
|
F
|
Forster, M;
Mendes, R;
Harrington, K;
Guerrero-Urbano, T;
Baines, H;
Spanswick, V;
Ensell, L;
... Beare, S; + view all
(2016)
A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck (HNSCC).
Presented at: 2016 ASCO Annual Meeting, Chicago, IL, USA.
|
G
|
Gleeson, M;
Hawkes, EA;
Cunningham, D;
Chadwick, N;
Counsell, N;
Lawrie, A;
Jack, A;
... Linch, D; + view all
(2016)
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.
British Journal of Haematology
, 175
(4)
pp. 668-672.
10.1111/bjh.14287.
|
|
Grunewald, T;
Ledermann, JA;
(2016)
Targeted Therapies for Ovarian Cancer.
Best Practice & Research Clinical Obstetrics & Gynaecology
10.1016/j.bpobgyn.2016.12.001.
(In press).
|
H
|
Heinrich, M;
Fisher, A;
Paton, B;
McCourt, O;
Beeken, RJ;
Hackshaw, A;
Wardle, J;
(2016)
Lifestyle in Multiple Myeloma - a longitudinal cohort study protocol.
BMC Cancer
, 16
, Article 387. 10.1186/s12885-016-2407-x.
|
|
|
Hirst, Y;
Kerrison, R;
Kobayashi, LC;
Counsell, N;
Djedovic, N;
Ruwende, J;
Stewart, M;
(2016)
Text Reminders in Colorectal Cancer Screening (TRICCS): Protocol for a randomised controlled trial.
BMC Public Health
10.1186/s12889-016-2733-6.
|
|
J
|
Johnson, P;
Federico, M;
Kirkwood, A;
Fossa, A;
Berkahn, L;
Carella, A;
d'Amore, F;
... Barrington, S; + view all
(2016)
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.
New England Journal of Medicine
, 374
(25)
pp. 2419-2429.
10.1056/NEJMoa1510093.
|
|
K
|
Kerrison, R;
McGregor, LM;
Marshall, S;
Isitt, J;
Counsell, N;
Wardle, J;
Von Wagner, C;
(2016)
Use of a twelve month's self referral reminder to faciliate uptake of bowel scope (flexible sigmoidoscopy screening) in previous non-responders: a London-based feasibility study.
British Journal of Cancer
, 114
pp. 751-758.
10.1038/bjc.2016.43.
|
|
|
Kerrison, RS;
McGregor, LM;
Marshall, S;
Isitt, J;
Counsell, N;
Wardle, J;
von Wagner, C;
(2016)
Use of a 12 months' self-referral reminder to facilitate uptake of bowel scope (flexible sigmoidoscopy) screening in previous non-responders: a London-based feasibility study.
British Journal of Cancer
, 114
(7)
pp. 751-758.
10.1038/bjc.2016.43.
|
|
|
Khoja, L;
Nolan, K;
Mekki, R;
Milani, A;
Mescallado, N;
Ashcroft, L;
Hasan, J;
... Jayson, GC; + view all
(2016)
Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK.
Clinical Oncology
, 28
(12)
pp. 760-765.
10.1016/j.clon.2016.06.011.
|
|
|
Kularatne, B;
Arora, R;
Elshstein, G;
Guppy, N;
Kirkwood, A;
Meyer, T;
Kristeleit, RS;
(2016)
Immunohistochemistry (IHC) evaluation of a novel 4-protein prognostic and predictive biomarker panel in endometrial cancer (EC).
In:
Abstract Book of the 41st ESMO Congress (ESMO 2016), 7-11 October 2016, Copenhagen, Denmar.
Oxford University Press (OUP): Policy A1
|
L
|
Landau, DB;
Hughes, L;
Baker, A;
Bates, AT;
Bayne, MC;
Counsell, N;
Garcia-Alonso, A;
... Fenwick, JD; + view all
(2016)
IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer.
International Journal of Radiation Oncology - Biology - Physics
, 95
(5)
pp. 1367-1377.
10.1016/j.ijrobp.2016.03.031.
|
|
|
Ledermann, JA;
(2016)
PARP inhibitors in ovarian cancer.
Annals of Oncology
, 27
(Suppl 1)
i40-i44.
10.1093/annonc/mdw094.
|
|
Ledermann, JA;
Drew, Y;
Kristeleit, RS;
(2016)
Homologous recombination deficiency and ovarian cancer.
European Journal of Cancer
, 60
pp. 49-58.
10.1016/j.ejca.2016.03.005.
|
|
Ledermann, JA;
Embleton, AC;
Raja, F;
Perren, TJ;
Jayson, GC;
Rustin, GJS;
Kaye, SB;
... Collaborators, I; + view all
(2016)
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet
, 387
(10023)
pp. 1066-1074.
10.1016/S0140-6736(15)01167-8.
|
|
Ledermann, JA;
Harter, P;
Gourley, C;
Friedlander, M;
Vergote, I;
Rustin, G;
Scott, C;
... Matulonis, U; + view all
(2016)
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
British Journal of Cancer
, 115
(11)
pp. 1313-1320.
10.1038/bjc.2016.348.
|
|
Ledermann, JA;
Harter, P;
Gourley, C;
Friedlander, M;
Vergote, I;
Rustin, G;
Scott, C;
... Matulonis, U; + view all
(2016)
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
The Lancet Oncology
, 17
(11)
pp. 1579-1589.
10.1016/S1470-2045(16)30376-X.
|
|
Lee, SM;
Falzon, M;
Blackhall, F;
Spicer, J;
Nicolson, M;
Chaudhuri, A;
Middleton, G;
... Hackshaw, A; + view all
(2016)
Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).
Journal of Clinical Oncology
, 35
(4)
pp. 402-411.
10.1200/JCO.2016.68.1841.
|
|
|
Lemech, CR;
Ensell, L;
Paterson, JC;
Eminowicz, G;
Lowe, H;
Arora, R;
Arkenau, H-T;
... Kristeleit, RS; + view all
(2016)
Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer.
Oncology
, 91
(1)
pp. 48-54.
10.1159/000445999.
|
M
|
Mateo, J;
Moreno, V;
Gupta, A;
Kaye, SB;
Dean, E;
Middleton, MR;
Friedlander, M;
... Molife, LR; + view all
(2016)
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.
Targeted Oncology
, 11
(3)
pp. 401-415.
10.1007/s11523-016-0435-8.
|
|
McGregor, L;
Von Wagner, C;
Atkin, W;
Kralj-Hans, I;
Halloran, S;
Handley, G;
Logan, R;
... Wardle, J; + view all
(2016)
Reducing the social gradient in uptake of the NHS Colorectal Cancer Screening Programme using a narrative-based information leaflet: a cluster-randomised trial.
Gastroenterology Research and Practice
, 2016
, Article 3670150. 10.1155/2016/3670150.
|
|
Miller, RE;
Ledermann, JA;
(2016)
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
Clinical Advances in Hematology & Oncology
, 14
(8)
pp. 619-627.
|
|
|
Miller, RE;
Ledermann, JA;
(2016)
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
Clinical Advances in Hematology & Oncology
, 14
(9)
pp. 704-711.
|
|
Mirza, MR;
Monk, BJ;
Herrstedt, J;
Oza, AM;
Mahner, S;
Redondo, A;
Fabbro, M;
... ENGOT-OV16/NOVA Investigators; + view all
(2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
The New England Journal of Medicine
, 375
(22)
pp. 2154-2164.
10.1056/NEJMoa1611310.
|
P
|
Patel, B;
Kirkwood, AA;
Dey, A;
Marks, DI;
McMillan, AK;
Menne, TF;
Micklewright, L;
... Fielding, AK; + view all
(2016)
Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial.
Leukemia
10.1038/leu.2016.219.
|
|
Perna, C;
Eminowicz, G;
Asghar, U;
Imseeh, G;
Kirkwood, A;
Mitra, A;
Arora, R;
... McCormack, M; + view all
(2016)
Uterine carcinosarcoma: a retrospective clinical cohort analysis.
Presented at: ESMO 2016: 41st ESMO Congress, Copenhagen, Denmark.
|
R
|
Raine, R;
Duffy, SW;
Wardle, J;
Solmi, F;
Morris, S;
Howe, R;
Kralj-Hans, I;
... Atkin, W; + view all
(2016)
Impact of general practice endorsement on the social gradient in uptake in bowel cancer screening.
British Journal of Cancer
, 114
pp. 321-326.
10.1038/bjc.2015.413.
|
|
Raine, R;
Moss, SM;
von Wagner, C;
Atkin, W;
Hans, IK;
Howe, R;
Solmi, F;
... Duffy, SW; + view all
(2016)
A national cluster-randomised controlled trial to examine the effect of enhanced reminders on the socioeconomic gradient in uptake in bowel cancer screening.
British Journal of Cancer
, 115
(12)
pp. 1479-1486.
10.1038/bjc.2016.365.
|
T
|
Townsend, W;
Johnson, RJ;
Pottinger, BT;
Counsell, N;
Smith, P;
Chadwick, H;
Evans, K;
... Rudin, CE; + view all
(2016)
A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320.
Leukemia & Lymphoma
, 57
(9)
pp. 2232-2234.
10.3109/10428194.2015.1133814.
|
U
|
UK CLL Forum;
(2016)
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.
Haematologica
, 101
(12)
pp. 1563-1572.
10.3324/haematol.2016.147900.
|
|
W
|
Wardle, J;
von Wagner, C;
Kralj-Hans, I;
Halloran, SP;
Smith, SG;
McGregor, LM;
Vart, G;
... Raine, R; + view all
(2016)
Effects of evidence-based strategies to reduce the socioeconomic gradient of uptake in the English NHS Bowel Cancer Screening Programme (ASCEND): four cluster-randomised controlled trials.
The Lancet
, 387
(10020)
pp. 751-759.
10.1016/S0140-6736(15)01154-X.
|
|
Wheeler, GM;
(2016)
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach.
Statistical Papers
pp. 1-11.
10.1007/s00362-016-0790-7.
|
|
Wheeler, GM;
Sweeting, MJ;
Mander, AP;
(2016)
AplusB: A Web Application for Investigating A plus B Designs for Phase I Cancer Clinical Trials.
PLOS ONE
, 11
(7)
, Article e0159026. 10.1371/journal.pone.0159026.
|
|
